dynaCERT GmbH Expands Operations with New Setup & Location at Munich Airport, Germany
dynaCERT Inc. (TSX: DYA) (OTC: DYFSF) (FRA: DMJ) is pleased to announce that its German subsidiary, dynaCERT GmbH, has relocated to a new facility at Munich Airport, Germany. The new location has been strategically chosen to enhance proximity to its targeted customers and strengthen operations in the European market.
To underline the importance of the German and European market as well as dynaCERT 's global sales efforts, Kevin Unrath has been appointed as Managing Director of dynaCERT GmbH, in addition to his role as COO of dynaCERT Inc. in Toronto.
'By relocating our office within Germany, we aim to be operationally closer to our targeted customers and partners. Munich is a key hub for many of the German and European Key Customers industries such as engines, Commercial Vehicles, Construction Industry and Industrial Solutions. With the upcoming government transition in Berlin, dynaCERT GmbH anticipates fresh momentum for German sales as an industrial powerhouse in the heart of Europe. We are excited to be more accessible than ever in this Region,' said Kevin Unrath, Managing Director of dynaCERT GmbH.
A major upcoming event for the construction industry and heavy equipment sector is 'bauma' in Munich, taking place from April 7 to April 13, 2025. As the world's largest trade fair regarding size in sqm. and visitors, dynaCERT will seize this opportunity to showcase its products and services by hosting an exclusive Event to potential customers, new leads and partners of dynaCERT from governmental, consulting and logistics organizations.
Exhibitors and visitors interested in scheduling a meeting with dynaCERT during bauma 2025 at our new German location are invited to contact the company at [email protected] or +49 (0) 89 – 9700 7015.
About dynaCERT Inc.
dynaCERT Inc. manufactures and distributes Carbon Emission Reduction Technology along with its proprietary HydraLytica™ Telematics, a means of monitoring fuel consumption and calculating GHG emissions savings designed for the tracking of possible future Carbon Credits for use with internal combustion engines. As part of the growing global hydrogen economy, our patented technology creates hydrogen and oxygen on-demand through a unique electrolysis system and supplies these gases through the air intake to enhance combustion, which has shown to lower carbon emissions and improve fuel efficiency. Our technology is designed for use with many types and sizes of diesel engines used in on-road vehicles, reefer trailers, off-road construction, power generation, mining and forestry equipment. Website: www. dynaCERT.com.
READER ADVISORY
This press release of dynaCERT Inc. contains statements that constitute 'forward-looking statements.' Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause dynaCERT's actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Actual results may vary from the forward-looking information in this news release due to certain material risk factors.
Except for statements of historical fact, this news release contains certain 'forward-looking information' within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as 'plan', 'expect', 'project', 'intend', 'believe', 'anticipate', 'estimate' and other similar words, or statements that certain events or conditions 'may' or 'will' occur. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance of achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.
Forward-looking information is based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: uncertainty as to whether our strategies and business plans will yield the expected benefits; availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; the uncertainty of the emerging hydrogen economy; including the hydrogen economy moving at a pace not anticipated; our ability to secure and maintain strategic relationships and distribution agreements; and the other risk factors disclosed under our profile on SEDAR at www.sedarplus.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.
The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.
Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of the release.
On Behalf of the Board
Murray James Payne, CEO
CONTACT: Jim Payne, Chairman & CEO
dynaCERT Inc.
#101 – 501 Alliance Avenue
Toronto, Ontario M6N 2J1
+1 (416) 766-9691 x 2
[email protected] Relations
dynaCERT Inc.
Nancy Massicotte
+1 (416) 766-9691 x 1
[email protected]
KEYWORD: GERMANY EUROPE NORTH AMERICA CANADA
INDUSTRY KEYWORD: OFF-ROAD TRUCKS & SUVS UTILITIES ALTERNATIVE ENERGY GENERAL AUTOMOTIVE PUBLIC TRANSPORT ENERGY OTHER CONSTRUCTION & PROPERTY AUTOMOTIVE CONSTRUCTION & PROPERTY TRUCKING RAIL MARITIME TRANSPORT
SOURCE: dynaCERT Inc.
Copyright Business Wire 2025.
PUB: 03/03/2025 05:00 AM/DISC: 03/03/2025 05:00 AM
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
34 minutes ago
- Yahoo
MediPharm Announces Complete Dismissal of Dissident Court Proceeding Related to Annual and Special Meeting
TORONTO, June 11, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ('MediPharm' or the 'Company'), a pharmaceutical company specialized in precision-based cannabinoids, today announced that the Superior Court of Justice – Ontario (Commercial List) (the 'Court') has fully dismissed the application (CV-25-00743454-00CL) (the 'Application') issued by Apollo Technology Capital Corporation ('Apollo') and Nobul Technologies Inc. (together with Apollo, the 'Applicants') against the Company on May 16, 2025 (the 'Notice'). The Applicants sought an order from the Court, amongst other things, appointing a third-party independent chair to preside over the Annual and Special Meeting of Shareholders of the Company (the 'Meeting') on June 16, 2025. The Applicants argued that MediPharm has a 'design or plan to invalidate proxies' and that the Company had acted improperly warranting the appointment of a third-party independent chair. The Court dismissed the Application in full. In doing so, the Court found that a third-party independent chair was not required in the circumstances as there was no evidence or indication that MediPharm's proposed meeting chair will act unfairly at the Meeting. Regarding the conduct of Apollo's principal, Mr. Regan McGee, the Court found: 'The evidence shows that Mr. McGee has threatened to release a draft press release which, among other things, compared Mr. Pidduck to known serial killers. Press Releases have also been issued by Mr. McGee or the Applicants which accuse MediPharm and the Board of securities fraud, breach of fiduciary duty and running a corrupt election process to entrench themselves. Mr. McGee has threatened to sue the Board by way of a derivative action for breach of fiduciary duty and associated damages because of the rejection of the $3.4 million offer and has commenced a lawsuit against MediPharm, two of its senior officers and directors, as well as the Company's external litigation firm (Tyr LLP) and counsel (James Bunting) which claimed $50 million in damages. Mr. McGee, repeated the allegations set out in the lawsuit in the Dissident Circular and then abandoned and withdrew the claim against Tyr LLP and Mr. Bunting, and agreed to terms of settlement that included a declaration by Mr. McGee that Tyr LLP and Mr. Bunting are not in a conflict of interest in acting for MediPharm, that they had not misused confidential information, that Mr. McGee would not disparage Mr. Bunting or Tyr LLP and provided a full release to Tyr LLP and Mr. Bunting.' The Company remains committed to a fair shareholder meeting process, in compliance with its constating documents and all applicable laws. We encourage shareholders to please vote using ONLY the GREEN proxy or GREEN voting instruction card and to support each of the director nominees recommended by MediPharm's Board of Directors (the 'Board') and the other matters being considered at the Meeting. To ensure your proxy is counted at the Meeting, please submit it well in advance of the June 13 proxy cut-off. Vote for the Highly Qualified MediPharm Nominees MediPharm urges shareholders to vote only using the GREEN proxy or GREEN voting instruction form in support of all of the Company's nominees and resolutions. To ensure your vote is counted, shareholders are encouraged to proactively contact their broker to obtain their 16-digit control number associated with the GREEN management proxy. Once received, you can cast your vote by visiting You may receive materials or outreach from the dissident — please disregard any such communications and vote only using the GREEN proxy in support of the Company's nominees. About MediPharm Labs Founded in 2015, MediPharm Labs specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products utilizing a Good Manufacturing Practices certified facility with ISO standard-built clean rooms. MediPharm Labs has invested in an expert, research driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities for delivery of pure, trusted and precision-dosed cannabis products for its customers. MediPharm Labs develops, formulates, processes, packages and distributes cannabis and advanced cannabinoid-based products to domestic and international medical markets. In 2021, MediPharm Labs received a Pharmaceutical Drug Establishment License from Health Canada, becoming the only company in North America to hold a commercial-scale domestic Good Manufacturing Practices License for the extraction of multiple natural cannabinoids. This GMP license was the first step in the Company's current foreign drug manufacturing site registration with the US FDA. In 2023, MediPharm acquired VIVO Cannabis Inc., which expanded MediPharm's reach to medical patients in Canada via Canna Farms medical ecommerce platform, and in Australia and Germany through Beacon Medical Australia PTY Ltd. and Beacon Medical Germany GMBH. This acquisition also included Harvest Medical Clinics in Canada which provides medical cannabis patients with Physician consultations for medical cannabis education and prescriptions. The Company carries out its operations in compliance with all applicable laws in the countries in which it operates. Shareholder Voting Assistance: If you have any questions or require any assistance in executing your GREEN proxy or voting instruction form, please call Sodali & Co at: North American Toll-Free Number: 1.888.777.2059Outside North America, Banks, Brokers and Collect Calls: 1.289.695.3075Email: assistance@ American Toll-Free Facsimile: 1.877.218.5372 For up-to-date information and assistance in voting please visit: Investor Contact: MediPharm Labs Investor RelationsTelephone: +1 416.913.7425Email: investors@ Media Contact: John VincicOakstrom Advisors+1 (647) 402-6375john@ Cautionary Note Regarding Forward-Looking Information: This news release contains 'forward-looking information' and 'forward-looking statements' (collectively, 'forward-looking statements') within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as 'expects', or 'does not expect', 'is expected', 'anticipates' or 'does not anticipate', 'plans', 'budget', 'scheduled', 'forecasts', 'estimates', 'believes' or 'intends' or variations of such words and phrases or stating that certain actions, events or results 'may' or 'could', 'would', 'might' or 'will' be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate to, among other things: timing of the Annual and Special Meeting, any impacts to MediPharm shareholders of the actions relating to the Applicants or Mr. McGee, and any outcomes resulting from the circumstances and information cited herein. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; the inability of MediPharm Labs to obtain adequate financing; the delay or failure to receive regulatory approvals; and other factors discussed in MediPharm Labs' continuous disclosure filings, available on the SEDAR+ website at There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, MediPharm Labs assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they in to access your portfolio
Yahoo
an hour ago
- Yahoo
Julius Baer Successfully Places EUR 500 Million Senior Unsecured Notes
ZURICH - June 11, 2025 (NEWMEDIAWIRE) - Today, Julius Baer Group Ltd. successfully placed EUR 500 million 5-year senior unsecured notes through ELM B.V., a repackaging issuance entity incorporated in the Netherlands. This EUR senior unsecured issuance allows Julius Baer to further diversify its funding strategy in international debt markets. The transaction was targeted at European institutional investors and the proceeds will be used for general corporate purposes. Julius Baer Group Ltd. will issue loan notes to, and which are held by, ELM B.V. (or a nominee acting on its behalf), which in turn will issue its own notes to investors secured by the Julius Baer Group Ltd. loan notes. The securities carry a fixed-rate, annually payable coupon set at 3.375% per annum and have been issued in denominations of EUR 100,000. An application for admission to trading of the notes issued by ELM B.V. on Euronext Dublin will be made. ContactsMedia Relations, tel. +41 (0) 58 888 8888Investor Relations, tel. +41 (0) 58 888 5256 This announcement is not and shall not be interpreted or construed as a solicitation to purchase any securities of/in Julius Baer Group. About Julius Baer Julius Baer is the leading Swiss wealth management group and a premium brand in this global sector, with a focus on servicing and advising sophisticated private clients. In all we do, we are inspired by our purpose: creating value beyond wealth. At the end of April 2025, assets under management amounted to CHF 467 billion. Bank Julius Baer & Co. Ltd., the renowned Swiss private bank with origins dating back to 1890, is the principal operating company of Julius Baer Group Ltd., whose shares are listed on the SIX Swiss Exchange (ticker symbol: BAER) and are included in the Swiss Leader Index (SLI), comprising the 30 largest and most liquid Swiss stocks. Julius Baer is present in around 25 countries and 60 locations. Headquartered in Zurich, we have offices in key locations including Bangkok, Dubai, Dublin, Frankfurt, Geneva, Hong Kong, London, Luxembourg, Madrid, Mexico City, Milan, Monaco, Mumbai, Santiago de Chile, Shanghai, Singapore, Tel Aviv, and Tokyo. Our client-centric approach, our objective advice based on the Julius Baer open product platform, our solid financial base, and our entrepreneurial management culture make us the international reference in wealth management. For more information visit our website at Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
David Ornstein Confirms Liverpool Striker Move is ‘Possible' After Recent Contact
Liverpool's Forward Focus: Nunez Exit Opens Door for Ekitike After Record-Breaking Wirtz Deal Liverpool's summer window has exploded into life, with business being conducted swiftly and decisively under Arne Slot. Florian Wirtz's arrival, confirmed late Tuesday, will not only obliterate the club's own transfer record but also set new benchmarks across English and German football. At a projected cost of over £115m, it surpasses the Moises Caicedo fee to Chelsea and signals a shift in how the Reds intend to compete. Advertisement As reported by The Athletic's David Ornstein, Wirtz's signing is not the end of Liverpool's spree. 'There is, meanwhile, a possible departure from Merseyside in the form of Darwin Nunez,' Ornstein noted, confirming contact from Al-Hilal for the Uruguayan. While the player is reportedly more inclined to remain in Europe, the financial pull from Saudi Arabia remains a factor. With Wirtz secured and Milos Kerkez close to completing a switch, Liverpool's net summer spend could soon exceed £195m. Yet, there is still desire for a new number nine – and Hugo Ekitike has emerged as the primary target. Ekitike Move Contingent on Outgoings Eintracht Frankfurt's €100m asking price for Ekitike has cooled Chelsea's interest, leaving Liverpool well-positioned – but only if two players depart. As per Sky Germany's Florian Plettenberg, Liverpool must sell two of Diogo Jota, Federico Chiesa or Darwin Nunez before advancing negotiations for the French forward. Photo: IMAGO The strongest indication of an imminent exit centres on Nunez, who has struggled to consistently justify his £85m price tag since joining from Benfica. Al-Hilal's recent inquiry represents a serious push to bring the Uruguayan to the Saudi Pro League, having previously missed out on Mohamed Salah, Bruno Fernandes and Victor Osimhen. Advertisement 'Liverpool rejected a proposal worth €70m from Al Nassr in January, and that sets a minimum bar if an exit is to materialise,' Ornstein wrote. That valuation remains the benchmark if the Reds are to part ways with the 24-year-old. Elliott and Gakpo Future Questions Wirtz's arrival also places questions around the futures of other attackers, particularly Harvey Elliott. The 22-year-old made his stance clear: 'I don't really want to be wasting years of my career because it's a short career.' With Wolves and Newcastle reportedly interested, Elliott's departure would ease squad congestion and raise additional funds. Meanwhile, Cody Gakpo has publicly rejected links to Bayern Munich, while Alisson Becker has reaffirmed his commitment to Anfield, though he has started exploring his next steps, according to reports. Photo: IMAGO Slot's Tactical Evolution Demands Precision Slot's system hinges on high-intensity pressing and fluid attacking movement – a style tailor-made for someone like Wirtz. The German's numbers last season were staggering: 45 appearances, 16 goals and 15 assists. It's a clear statement of intent from Liverpool and an evolution from the more chaotic attacking presence of Nunez. Advertisement Wirtz also represents the most expensive German footballer ever, Bayer Leverkusen's record sale, and the Bundesliga's highest transfer fee to date. It is a transformative deal both on and off the pitch. Our View – Anfield Index Analysis There's a strange inevitability to Darwin Nunez's likely departure. His raw energy and unpredictability created moments of brilliance, but not the consistency a title-winning side demands. With Arne Slot at the helm and Liverpool now reigning champions again, the standards have shifted. Every decision must be calculated, and emotion cannot drive the future. Florian Wirtz is the opposite type of forward – intelligent, composed and ruthlessly efficient. He feels like a player designed for Slot's tactics. His arrival is exciting, but fans will rightly wonder if Liverpool will regret letting Nunez go just as he might have reached his peak. Advertisement The Ekitike interest is intriguing. He's younger, mouldable and potentially a better long-term fit. But can he adapt quickly enough to the Premier League, and will he thrive in the pressure cooker of Anfield? That remains a gamble. Harvey Elliott's frustration is understandable, and while it would hurt to lose a homegrown star, this is a ruthless business now. Wirtz's signing shows Liverpool's hand – trophies are the priority. And if the money from Saudi helps complete that vision, fans may just get behind it, however conflicted they feel.
